

Ross McKinnon

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4179545/publications.pdf>

Version: 2024-02-01

142
papers

5,424
citations

100601

38
h-index

111975

67
g-index

144
all docs

144
docs citations

144
times ranked

7916
citing authors

#	ARTICLE	IF	CITATIONS
1	Extended RAS mutations and anti-EGFR monoclonal antibody survival benefit in metastatic colorectal cancer: a meta-analysis of randomized, controlled trials. <i>Annals of Oncology</i> , 2015, 26, 13-21.	0.6	439
2	Meta-analysis of BRAF mutation as a predictive biomarker of benefit from anti-EGFR monoclonal antibody therapy for RAS wild-type metastatic colorectal cancer. <i>British Journal of Cancer</i> , 2015, 112, 1888-1894.	2.9	272
3	PREDICTING HUMAN DRUG GLUCURONIDATION PARAMETERS: Application of In Vitro and In Silico Modeling Approaches. <i>Annual Review of Pharmacology and Toxicology</i> , 2004, 44, 1-25.	4.2	203
4	The UDP-Glycosyltransferase (UGT) Superfamily: New Members, New Functions, and Novel Paradigms. <i>Physiological Reviews</i> , 2019, 99, 1153-1222.	13.1	185
5	Genetic polymorphisms of UDP-glucuronosyltransferases and their functional significance. <i>Toxicology</i> , 2002, 181-182, 453-456.	2.0	176
6	Cyp1a2(-/-) null mutant mice develop normally but show deficient drug metabolism.. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1996, 93, 1671-1676.	3.3	158
7	Predicting response and toxicity to immune checkpoint inhibitors using routinely available blood and clinical markers. <i>British Journal of Cancer</i> , 2017, 117, 913-920.	2.9	145
8	Reply: Comment on "Meta-analysis of BRAF mutation as a predictive biomarker of benefit from anti-EGFR monoclonal-antibody therapy for RAS wild-type metastatic colorectal cancer". <i>British Journal of Cancer</i> , 2015, 113, 1635-1635.	2.9	127
9	Characterisation of CYP3A gene subfamily expression in human gastrointestinal tissues.. <i>Gut</i> , 1995, 36, 259-267.	6.1	125
10	Manipulation of the gut microbiota using resistant starch is associated with protection against colitis-associated colorectal cancer in rats. <i>Carcinogenesis</i> , 2016, 37, 366-375.	1.3	121
11	CYP2C19 Genotype Has a Greater Effect on Adverse Cardiovascular Outcomes Following Percutaneous Coronary Intervention and in Asian Populations Treated With Clopidogrel. <i>Circulation: Cardiovascular Genetics</i> , 2014, 7, 895-902.	5.1	107
12	Polymorphisms in UDP Glucuronosyltransferase Genes: Functional Consequences and Clinical Relevance. <i>Clinical Chemistry and Laboratory Medicine</i> , 2000, 38, 889-92.	1.4	97
13	Prasugrel vs. clopidogrel for cytochrome P450 2C19 genotyped subgroups: integration of the TRITON-TIMI 38 trial data. <i>Journal of Thrombosis and Haemostasis</i> , 2010, 8, 1678-1684.	1.9	92
14	Transcriptional regulation of human UDP-glucuronosyltransferase genes. <i>Drug Metabolism Reviews</i> , 2014, 46, 421-458.	1.5	90
15	Comparison of Linear and Nonlinear Classification Algorithms for the Prediction of Drug and Chemical Metabolism by Human UDP-Glucuronosyltransferase Isoforms. <i>Journal of Chemical Information and Computer Sciences</i> , 2003, 43, 2019-2024.	2.8	87
16	Localization of CYP1A1 and CYP1A2 messenger RNA in normal human liver and in hepatocellular carcinoma by in situ hybridization. <i>Hepatology</i> , 1991, 14, 848-856.	3.6	85
17	miR-18a Inhibits CDC42 and Plays a Tumour Suppressor Role in Colorectal Cancer Cells. <i>PLoS ONE</i> , 2014, 9, e112288.	1.1	84
18	Complementary and alternative medicines and dietary interventions in multiple sclerosis: What is being used in South Australia and why?. <i>Complementary Therapies in Medicine</i> , 2009, 17, 216-223.	1.3	80

#	ARTICLE	IF	CITATIONS
19	Cytochrome P450 structureâ€“function: insights from molecular dynamics simulations. <i>Drug Metabolism Reviews</i> , 2016, 48, 434-452.	1.5	79
20	Pharmacophore and quantitative structure activity relationship modelling of UDP-glucuronosyltransferase 1A1 (UGT1A1) substrates. <i>Pharmacogenetics and Genomics</i> , 2002, 12, 635-645.	5.7	75
21	Micromanaging aerobic respiration and glycolysis in cancer cells. <i>Molecular Metabolism</i> , 2019, 23, 98-126.	3.0	73
22	Pharmacophore and Quantitative Structureâ”Activity Relationship Modeling:Â Complementary Approaches for the Rationalization and Prediction of UDP-Glucuronosyltransferase 1A4 Substrate Selectivity. <i>Journal of Medicinal Chemistry</i> , 2003, 46, 1617-1626.	2.9	70
23	Prediction of Metabolism by Cytochrome P450 2C9: Alignment and Docking Studies of a Validated Database of Substrates. <i>Journal of Medicinal Chemistry</i> , 2008, 51, 780-791.	2.9	70
24	Biosimilarity and Interchangeability: Principles and Evidence: A Systematic Review. <i>BioDrugs</i> , 2018, 32, 27-52.	2.2	69
25	Partial Charge Calculation Method Affects CoMFA QSAR Prediction Accuracy. <i>Journal of Chemical Information and Modeling</i> , 2009, 49, 704-709.	2.5	67
26	Inhibition of human UDP-glucuronosyltransferase enzymes by lapatinib, pazopanib, regorafenib and sorafenib: Implications for hyperbilirubinemia. <i>Biochemical Pharmacology</i> , 2017, 129, 85-95.	2.0	64
27	Genetic polymorphisms of human UDP-glucuronosyltransferase (UGT) genes and cancer risk. <i>Drug Metabolism Reviews</i> , 2016, 48, 47-69.	1.5	62
28	Multiple Pharmacophores for the Investigation of Human UDP-Glucuronosyltransferase Isoform Substrate Selectivity. <i>Molecular Pharmacology</i> , 2004, 65, 301-308.	1.0	61
29	Towards integrated ADME prediction: past, present and future directions for modelling metabolism by UDP-glucuronosyltransferases. <i>Journal of Molecular Graphics and Modelling</i> , 2004, 22, 507-517.	1.3	57
30	Genetic Polymorphisms in Human Drug-Metabolizing Enzymes: Potential Uses of Reverse Genetics to Identify Genes of Toxicological Relevance. <i>Critical Reviews in Toxicology</i> , 1997, 27, 199-222.	1.9	52
31	Kinase inhibitor pharmacokinetics: comprehensive summary and roadmap for addressing inter-individual variability in exposure. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2017, 13, 31-49.	1.5	52
32	Binding of clozapine to the GABAB receptor: clinical and structural insights. <i>Molecular Psychiatry</i> , 2020, 25, 1910-1919.	4.1	52
33	Impact of theUGT1A1*28allele on response to irinotecan: a systematic review and meta-analysis. <i>Pharmacogenomics</i> , 2012, 13, 889-899.	0.6	51
34	A Novel Function for UDP Glycosyltransferase 8: Galactosidation of Bile Acids. <i>Molecular Pharmacology</i> , 2015, 87, 442-450.	1.0	51
35	Rapid Prediction of Chemical Metabolism by Human UDP-glucuronosyltransferase Isoforms Using Quantum Chemical Descriptors Derived with the Electronegativity Equalization Method. <i>Journal of Medicinal Chemistry</i> , 2004, 47, 5311-5317.	2.9	49
36	Consumers' views of pharmacogeneticsâ€“A qualitative study. <i>Research in Social and Administrative Pharmacy</i> , 2010, 6, 221-231.	1.5	49

#	ARTICLE	IF	CITATIONS
37	Supplementation with Brazil nuts and green tea extract regulates targeted biomarkers related to colorectal cancer risk in humans. <i>British Journal of Nutrition</i> , 2016, 116, 1901-1911.	1.2	49
38	Role of CYP2A5 and 2G1 in Acetaminophen Metabolism and Toxicity in the Olfactory Mucosa of the Cyp1a2(âˆ’/âˆ’)Mouse. <i>Biochemical Pharmacology</i> , 1998, 55, 1819-1826.	2.0	46
39	Deregulation of the Genes that Are Involved in Drug Absorption, Distribution, Metabolism, and Excretion in Hepatocellular Carcinoma. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2019, 368, 363-381.	1.3	43
40	Regulation of Human UGT2B15 and UGT2B17 by miR-376c in Prostate Cancer Cell Lines. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2015, 354, 417-425.	1.3	39
41	Effectiveness of the Pharmacist-Involved Multidisciplinary Management of Heart Failure to Improve Hospitalizations and Mortality Rates in 4630 Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. <i>Journal of Cardiac Failure</i> , 2019, 25, 744-756.	0.7	38
42	Localization of cytochromes p450 in human tissues: implications for chemical toxicity. <i>Pathology</i> , 1996, 28, 148-155.	0.3	36
43	Polymorphic variations in the expression of the chemical detoxifying UDP glucuronosyltransferases. <i>Toxicology and Applied Pharmacology</i> , 2005, 207, 77-83.	1.3	36
44	The effect of the UGT1A1*28 allele on survival after irinotecan-based chemotherapy: a collaborative meta-analysis. <i>Pharmacogenomics Journal</i> , 2014, 14, 424-431.	0.9	36
45	The Importance of Local Chemical Structure for Chemical Metabolism by Human Uridine 5â€-Diphosphateâˆ’Glucuronosyltransferase. <i>Journal of Chemical Information and Modeling</i> , 2006, 46, 2692-2697.	2.5	35
46	Combination breast cancer chemotherapy with doxorubicin and cyclophosphamide damages bone and bone marrow in a female rat model. <i>Breast Cancer Research and Treatment</i> , 2017, 165, 41-51.	1.1	34
47	Impact of Histone Deacetylase Inhibitors on microRNA Expression and Cancer Therapy: A Review. <i>Drug Development Research</i> , 2015, 76, 296-317.	1.4	33
48	Baseline tumor size and survival outcomes in lung cancer patients treated with immune checkpoint inhibitors. <i>Seminars in Oncology</i> , 2019, 46, 380-384.	0.8	33
49	Meta-analysis comparing the efficacy of anti-EGFR monoclonal antibody therapy between KRAS G13D and other KRAS mutant metastatic colorectal cancer tumours. <i>European Journal of Cancer</i> , 2016, 55, 122-130.	1.3	32
50	Combination chemotherapy with cyclophosphamide, epirubicin and 5-fluorouracil causes trabecular bone loss, bone marrow cell depletion and marrow adiposity in female rats. <i>Journal of Bone and Mineral Metabolism</i> , 2016, 34, 277-290.	1.3	32
51	Premenstrual Syndrome and Spironolactone. <i>Australian and New Zealand Journal of Obstetrics and Gynaecology</i> , 1991, 31, 366-368.	0.4	30
52	An Overview of Current Regulatory Requirements for Approval of Biosimilar Insulins. <i>Diabetes Technology and Therapeutics</i> , 2015, 17, 510-526.	2.4	30
53	Lymphocytes of BRCA1 and BRCA2 germ-line mutation carriers, with or without breast cancer, are not abnormally sensitive to the chromosome damaging effect of moderate folate deficiency. <i>Carcinogenesis</i> , 2006, 27, 517-524.	1.3	29
54	Evaluation of the anti-inflammatory properties of <i>Dodonaea polyandra</i> , a Kaanju traditional medicine. <i>Journal of Ethnopharmacology</i> , 2010, 132, 340-343.	2.0	29

#	ARTICLE	IF	CITATIONS
55	In Vivo Activity of Benzoyl Ester Clerodane Diterpenoid Derivatives from <i>Dodonaea polyandra</i> . Journal of Natural Products, 2011, 74, 650-657.	1.5	27
56	Flavonoids from the leaves and stems of <i>Dodonaea polyandra</i> : A Northern Kaanju medicinal plant. Phytochemistry, 2011, 72, 1883-1888.	1.4	26
57	Induction of Human UDP-Glucuronosyltransferase 2B7 Gene Expression by Cytotoxic Anticancer Drugs in Liver Cancer HepG2 Cells. Drug Metabolism and Disposition, 2015, 43, 660-668.	1.7	25
58	Possible Role of Cytochromes P450 in Lupus Erythematosus and Related Disorders. Lupus, 1994, 3, 473-478.	0.8	24
59	Optimizing bacterial expression of catalytically active human cytochromes P450: comparison of CYP2C8 and CYP2C9. Xenobiotica, 2004, 34, 49-60.	0.5	23
60	Methionine-Dependence Phenotype in the <i>de novo</i> Pathway in BRCA1 and BRCA2 Mutation Carriers with and without Breast Cancer. Cancer Epidemiology Biomarkers and Prevention, 2008, 17, 2565-2571.	1.1	23
61	The role and utility of measuring red blood cell methotrexate polyglutamate concentrations in inflammatory arthropathies—a systematic review. European Journal of Clinical Pharmacology, 2015, 71, 411-423.	0.8	23
62	Regulation of UDP-Glucuronosyltransferases UGT2B4 and UGT2B7 by MicroRNAs in Liver Cancer Cells. Journal of Pharmacology and Experimental Therapeutics, 2017, 361, 386-397.	1.3	23
63	Recent Advances in the In Silico Modelling of UDP Glucuronosyltransferase Substrates. Current Drug Metabolism, 2008, 9, 60-69.	0.7	22
64	Integrated care in cancer: What is it, how is it used and where are the gaps? A textual narrative literature synthesis. European Journal of Cancer Care, 2017, 26, e12689.	0.7	22
65	Insights into the UDP-sugar selectivities of human UDP-glycosyltransferases (UGT): a molecular modeling perspective. Drug Metabolism Reviews, 2015, 47, 335-45.	1.5	21
66	Cytochrome P450: evolution and functional diversity. Progress in Liver Diseases, 1994, 12, 63-97.	0.3	21
67	Species-specific expression of CYP4B1 in rabbit and human gastrointestinal tissues. Pharmacogenetics and Genomics, 1994, 4, 260-270.	5.7	20
68	In silico insights: Chemical and structural characteristics associated with uridine diphosphate-glucuronosyltransferase substrate selectivity. Clinical and Experimental Pharmacology and Physiology, 2003, 30, 836-840.	0.9	20
69	Is urinary indolyl-3-acryloylglycine a biomarker for autism with gastrointestinal symptoms?. Biomarkers, 2009, 14, 596-603.	0.9	20
70	Polymorphisms and Haplotypes of the UDP-Glucuronosyltransferase 2B7 Gene Promoter. Drug Metabolism and Disposition, 2014, 42, 854-862.	1.7	20
71	Role of the Pharmacist for Improving Self-care and Outcomes in Heart Failure. Current Heart Failure Reports, 2017, 14, 78-86.	1.3	20
72	Cloning and expression of koala (<i>Phascolarctos cinereus</i>) liver cytochrome P450 CYP4A15. Gene, 2006, 376, 123-132.	1.0	19

#	ARTICLE	IF	CITATIONS
73	Personalized Medicine: Potential, Barriers and Contemporary Issues. <i>Current Drug Metabolism</i> , 2012, 13, 1000-1006.	0.7	19
74	Polyandric Acid A, a Clerodane Diterpenoid from the Australian Medicinal Plant <i>Dodonaea polyandra</i> , Attenuates Pro-inflammatory Cytokine Secretion in Vitro and in Vivo. <i>Journal of Natural Products</i> , 2014, 77, 85-91.	1.5	19
75	CYTOCHROME P450 KNOCKOUT MICE: NEW TOXICOLOGICAL MODELS. <i>Clinical and Experimental Pharmacology and Physiology</i> , 1998, 25, 783-787.	0.9	18
76	Comparison Data Sets for Benchmarking QSAR Methodologies in Lead Optimization. <i>Journal of Chemical Information and Modeling</i> , 2009, 49, 1810-1820.	2.5	18
77	Atorvastatin-induced cell toxicity in yeast is linked to disruption of protein isoprenylation. <i>FEMS Yeast Research</i> , 2010, 10, 188-198.	1.1	18
78	Global Supply of Health Professionals. <i>New England Journal of Medicine</i> , 2014, 370, 2246-2248.	13.9	18
79	Low adoption of pharmacogenetic testing: an exploration and explanation of the reasons in Australia. <i>Personalized Medicine</i> , 2007, 4, 191-199.	0.8	16
80	Generic substitution in the treatment of epilepsy: Patient attitudes and perceptions. <i>Epilepsy and Behavior</i> , 2013, 26, 64-66.	0.9	16
81	Investigation of <i>HTR3C</i> mutations for association with 5HT ₃ receptor antagonist anti-emetic efficacy. <i>Pharmacogenomics</i> , 2008, 9, 1027-1033.	0.6	15
82	Rare, seven-membered cyclic ether labdane diterpenoid from <i>Dodonaea polyandra</i> . <i>Phytochemistry</i> , 2012, 84, 141-146.	1.4	15
83	The Routine Clinical use of Pharmacogenetic Tests: What it Will Require?. <i>Pharmaceutical Research</i> , 2017, 34, 1544-1550.	1.7	15
84	Novel Nine-Exon AR Transcripts (Exon 1/Exon 1b/Exons 2-8) in Normal and Cancerous Breast and Prostate Cells. <i>International Journal of Molecular Sciences</i> , 2017, 18, 40.	1.8	15
85	Sustained improvement in vancomycin dosing and monitoring post-implementation of guidelines: Results of a three-year follow-up after a multifaceted intervention in an Australian teaching hospital. <i>Journal of Infection and Chemotherapy</i> , 2018, 24, 103-109.	0.8	15
86	The Expression Profiles and Deregulation of UDP-Glycosyltransferase (UGT) Genes in Human Cancers and Their Association with Clinical Outcomes. <i>Cancers</i> , 2021, 13, 4491.	1.7	15
87	Characterisation of tolbutamide hydroxylase activity in the common brushtail possum, (<i>Trichosurus</i>) Tj ETQq1 1 0.784314 rgBT /Over Comparative Biochemistry and Physiology C, <i>Comparative Pharmacology and Toxicology</i> , 2000, 127, 351-357.	0.5	14
88	Antiproliferative Aporphine Alkaloids from <i>Litsea glutinosa</i> and Ethnopharmacological Relevance to Kuuku It'yu Traditional Medicine. <i>Australian Journal of Chemistry</i> , 2016, 69, 145.	0.5	14
89	Hepatic cytochrome P450 enzymes belonging to the CYP2C subfamily from an Australian marsupial, the koala (<i>Phascolarctos cinereus</i>). <i>Comparative Biochemistry and Physiology Part - C: Toxicology and Pharmacology</i> , 2008, 148, 230-237.	1.3	13
90	Exploration of the perceptions, barriers and drivers of pharmacogenomics practice among hospital pharmacists in Adelaide, South Australia. <i>Pharmacogenomics Journal</i> , 2014, 14, 235-240.	0.9	13

#	ARTICLE	IF	CITATIONS
91	Regulation of UDP-Glucuronosyltransferase 2B15 by miR-331-5p in Prostate Cancer Cells Involves Canonical and Noncanonical Target Sites. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2018, 365, 48-59.	1.3	13
92	Marine bioactives: from energy to nutrition. <i>Trends in Biotechnology</i> , 2022, 40, 271-280.	4.9	13
93	Learning from Both Sides: Experiences and Opportunities in the Investigation of Australian Aboriginal Medicinal Plants. <i>Journal of Pharmacy and Pharmaceutical Sciences</i> , 2013, 16, 259.	0.9	12
94	Induction of UDP-Glucuronosyltransferase 2B15 Gene Expression by the Major Active Metabolites of Tamoxifen, 4-Hydroxytamoxifen and Endoxifen, in Breast Cancer Cells. <i>Drug Metabolism and Disposition</i> , 2015, 43, 889-897.	1.7	12
95	Junior doctors' preparedness to prescribe, monitor, and treat patients with the antibiotic vancomycin in an Australian teaching hospital. <i>Journal of Educational Evaluation for Health Professions</i> , 2017, 14, 13.	5.9	12
96	Effect of steric molecular field settings on CoMFA predictivity. <i>Journal of Molecular Modeling</i> , 2008, 14, 59-67.	0.8	11
97	Is there a role for routinely screening children with autism spectrum disorder for creatine deficiency syndrome?. <i>Autism Research</i> , 2010, 3, 268-272.	2.1	11
98	Educating Our Students About Pharmaceutical Care for Those Living With Cancer. <i>American Journal of Pharmaceutical Education</i> , 2012, 76, 119.	0.7	11
99	A novel approach for the simultaneous quantification of 18 small molecule kinase inhibitors in human plasma: A platform for optimised KI dosing. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2016, 1033-1034, 17-26.	1.2	11
100	The impact of a pilot continuing professional development module on hospital pharmacists' preparedness to provide contemporary advice on the clinical use of vancomycin. <i>SpringerPlus</i> , 2016, 5, 331.	1.2	11
101	Interventions targeting the prescribing and monitoring of vancomycin for hospitalized patients: a systematic review with meta-analysis. <i>Infection and Drug Resistance</i> , 2018, Volume 11, 2081-2094.	1.1	11
102	Cloning and expression of koala (<i>Phascolarctos cinereus</i>) liver cytochrome P450 reductase. <i>Comparative Biochemistry and Physiology Part - C: Toxicology and Pharmacology</i> , 2009, 150, 1-9.	1.3	10
103	The MEF2 gene is essential for yeast longevity, with a dual role in cell respiration and maintenance of mitochondrial membrane potential. <i>FEBS Letters</i> , 2011, 585, 1140-1146.	1.3	10
104	Transforming Pharmaceutical Education to Accelerate the Acceptance and Implementation of Personalized Medicine. <i>American Journal of Pharmaceutical Education</i> , 2011, 75, 107.	0.7	10
105	A Fragment-Based Approach for the Computational Prediction of the Nonspecific Binding of Drugs to Hepatic Microsomes. <i>Drug Metabolism and Disposition</i> , 2016, 44, 1794-1798.	1.7	10
106	Palliative Care Is Everyone's Business, Including Pharmacists. <i>American Journal of Pharmaceutical Education</i> , 2013, 77, 21.	0.7	9
107	Intergenic Splicing between Four Adjacent UGT Genes (UGT2B15, 2B29P2, 2B17, 2B29P1) Gives Rise to Variant UGT Proteins That Inhibit Glucuronidation via Protein-Protein Interactions. <i>Molecular Pharmacology</i> , 2018, 94, 938-952.	1.0	9
108	Nuances to precision dosing strategies of targeted cancer medicines. <i>Pharmacology Research and Perspectives</i> , 2020, 8, e00625.	1.1	9

#	ARTICLE	IF	CITATIONS
109	Systematic Statistical Comparison of Comparative Molecular Similarity Indices Analysis Molecular Fields for Computer-Aided Lead Optimization. <i>Journal of Chemical Information and Modeling</i> , 2006, 46, 2015-2021.	2.5	8
110	Cooperative Regulation of Intestinal UDP-Glucuronosyltransferases 1A8, -1A9, and 1A10 by CDX2 and HNF4α Is Mediated by a Novel Composite Regulatory Element. <i>Molecular Pharmacology</i> , 2018, 93, 541-552.	1.0	8
111	Editorial: Safety considerations of biosimilars. <i>Australian Prescriber</i> , 2016, 39, 188-189.	0.5	8
112	Cytochrome P450 CYP3A in marsupials: Cloning and identification of the first CYP3A subfamily member, isoform 3A70 from Eastern gray kangaroo (<i>Macropus giganteus</i>). <i>Gene</i> , 2012, 506, 423-428.	1.0	7
113	Cytochrome P450 1. Multiplicity and Function. <i>Journal of Pharmacy Practice and Research</i> , 2000, 30, 54-56.	0.2	6
114	Development and Evaluation of a Topical Anti-Inflammatory Preparation Containing <i>Dodonaea polyandra</i> Extract. <i>Journal of Pharmacy and Pharmaceutical Sciences</i> , 2015, 18, 578.	0.9	6
115	Exemestane and Its Active Metabolite 17-Hydroexemestane Induce UDP-Glucuronosyltransferase (UGT) 2B17 Expression in Breast Cancer Cells. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2017, 361, 482-491.	1.3	6
116	Interventions Targeting the Prescribing and Monitoring of Vancomycin for Hospitalized Patients: A Systematic Review Protocol. <i>Infectious Diseases and Therapy</i> , 2017, 6, 557-563.	1.8	6
117	Prediction of severe neutropenia and diarrhoea in breast cancer patients treated with abemaciclib. <i>Breast</i> , 2021, 58, 57-62.	0.9	6
118	HUMAN THIOPURINE METHYLTRANSFERASE: NO EVIDENCE OF ACTIVATION BY ITS SUBSTRATES. <i>Life Sciences</i> , 1997, 62, 343-350.	2.0	5
119	The Effect of Molecular Fields, Lattice Spacing and Analysis Options on CoMFA Predictive Ability. <i>QSAR and Combinatorial Science</i> , 2009, 28, 637-644.	1.5	5
120	Cytochrome P450 CYP3A in marsupials: Cloning and characterisation of the second identified CYP3A subfamily member, isoform 3A78 from koala (<i>Phascolarctos cinereus</i>). <i>Comparative Biochemistry and Physiology Part - C: Toxicology and Pharmacology</i> , 2011, 154, 367-376.	1.3	5
121	Polymorphisms in the Mitochondrial Ribosome Recycling Factor EF-G2mt/MEF2 Compromise Cell Respiratory Function and Increase Atorvastatin Toxicity. <i>PLoS Genetics</i> , 2012, 8, e1002755.	1.5	5
122	Knowledge and Perceptions of Community Patients about Generic Medicines. <i>Journal of Pharmacy Practice and Research</i> , 2012, 42, 283-286.	0.5	5
123	Arid awakening: new opportunities for Australian plant natural product research. <i>Rangeland Journal</i> , 2016, 38, 467.	0.4	5
124	Biosimilars are not (bio)generics. <i>Australian Prescriber</i> , 2009, 32, 146-147.	0.5	4
125	Correlation Between Peroxisome Proliferation and Up-Regulation of Cytochrome P450 CYP4A and Peroxisomal Beta-Oxidation Fatty Acyl CoA Oxidases (AOX) in the Koala (<i>Phascolarctos Cinereus</i>). <i>Gene Expression To Genetical Genomics</i> , 0, , 1.	1.0	4
126	Testosterone dehydrogenase activity in koala liver: characterisation of cofactor and steroid substrate differences. <i>Comparative Biochemistry and Physiology C, Comparative Pharmacology and Toxicology</i> , 2000, 125, 245-250.	0.5	3

#	ARTICLE	IF	CITATIONS
127	The Emergence of Pharmacogenomics. <i>Journal of Pharmacy Practice and Research</i> , 2003, 33, 133-137.	0.5	3
128	Pulmonary cytochrome P450 enzymes belonging to the CYP4B subfamily from an Australian marsupial, the tammar wallaby (<i>Macropus eugenii</i>). <i>Comparative Biochemistry and Physiology Part - C: Toxicology and Pharmacology</i> , 2011, 153, 60-66.	1.3	3
129	Reforming Pharmaceutical Education to Enhance the Global Uptake of Pharmacogenomics and Personalized Medicine. <i>Current Pharmacogenomics and Personalized Medicine</i> , 2012, 10, 231-238.	0.2	3
130	Smoking and immunotherapy efficacy in lung cancer by PDL1 subgroups: An individual participant data meta-analysis of atezolizumab clinical trials. <i>European Journal of Cancer</i> , 2022, 160, 279-281.	1.3	3
131	Low-molecular-weight heparin biosimilars: potential implications for clinical practice. <i>Internal Medicine Journal</i> , 2014, 44, 497-500.	0.5	2
132	Pharmacogenomics and Personalised Medicine: Consumer Perspectives, Lessons Learned in Australia and Beyond. <i>Current Pharmacogenomics and Personalized Medicine</i> , 2012, 10, 170-177.	0.2	1
133	<i>In vitro</i> metabolism of the anti-inflammatory clerodane diterpenoid polyandric acid A and its hydrolysis product by human liver microsomes and recombinant cytochrome P450 and UDP-glucuronosyltransferase enzymes. <i>Xenobiotica</i> , 2017, 47, 461-469.	0.5	1
134	Clinical translation of predictive markers for anti-EGFR monoclonal antibody therapy in metastatic colorectal cancer. <i>Translational Cancer Research</i> , 2016, 5, S31-S34.	0.4	1
135	Breaking the Silos: Integrated Care for Cancer and Chronic Conditions. , 2016, , 287-313.		1
136	Young-Onset Gastrointestinal Adenocarcinoma Incidence and Survival Trends in the Northern Territory, Australia, with Emphasis on Indigenous Peoples. <i>Cancers</i> , 2022, 14, 2870.	1.7	1
137	The Management of Polypharmacy in People with Cancer and Chronic Conditions. , 2016, , 261-286.		0
138	Transcriptional up-regulation of human udp-glucuronosyltransferase (UGT) 2B17 by exemestane and its active metabolite 17-hydroexemestane in breast cancer cells. <i>Drug Metabolism and Pharmacokinetics</i> , 2017, 32, S61.	1.1	0
139	PPAR-Alpha Cloning, Expression, and Characterization. <i>Methods in Molecular Biology</i> , 2013, 952, 7-34.	0.4	0
140	Editorial: CPPM 2013 Onward: Building a Socio-Technical GPS for Global Personalized Medicine – A Welcome to Editors-In-Chief Adrian LLerena (Spain) and Ross A. McKinnon (Australia). <i>Current Pharmacogenomics and Personalized Medicine</i> , 2013, 11, 87-92.	0.2	0
141	Pharmacogenomics in a Global World: A Roadmap for Australia, Prospects and Challenges. <i>Current Pharmacogenomics and Personalized Medicine</i> , 2014, 11, 257-259.	0.2	0
142	BRAF V600E and survival benefit of anti-EGFR monoclonal antibody (mAb) therapy for metastatic colorectal cancer (mCRC): A meta-analysis.. <i>Journal of Clinical Oncology</i> , 2015, 33, e14605-e14605.	0.8	0